Auris Medical : development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders like tinnitus and hearing loss     Print Page | Close Window

SEC Filings

AURIS MEDICAL HOLDING AG filed this Form 424B3 on 04/26/2017
Entire Document


Auris Medical Holding AG


We are a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidates are in Phase 3 clinical development. Keyzilen® (AM-101) is being developed for the treatment of acute inner ear tinnitus and has received fast track designation from the FDA. AM-111 is being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. AM-125 is being developed for the treatment of vestibular disorders. In addition, we are pursuing early stage projects for the treatment of tinnitus and rhinology.


We are a stock corporation organized under the laws of Switzerland. We began our current operations in 2003.


Our principal office is located at Bahnhofstrasse 21, 6300 Zug, Switzerland, telephone number +41 729 71 94. We maintain a website at where general information about us is available. Investors can obtain copies of our filings with the Securities and Exchange Commission, or SEC, from this site free of charge, as well as from the SEC website at We are not incorporating the contents of our website into this prospectus.


Risk Factors


Before making a decision to invest in our securities, you should carefully consider the risks described under “Risk Factors” in the applicable prospectus supplement and in our then most recent Annual Report on Form 20-F, and in any updates to those risk factors in our reports on Form 6-K incorporated herein, together with all of the other information appearing or incorporated by reference in this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances.


Ratio of Earnings to Fixed Charges


The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated. You should read this table in conjunction with the consolidated financial statements and notes incorporated by reference in this prospectus.



Fiscal Year Ended December 31,





Ratio of earnings to fixed charges * * *

* Our earnings were insufficient to cover fixed charges by CHF 673,390, CHF 94,732 and CHF 38,000 for the years ended December 31, 2016, 2015 and 2014, respectively.


For purposes of calculating the ratios in the table above, earnings consist of net profit/(loss) before income taxes plus fixed charges. Fixed charges consist of rental expenses and cash relevant interest expenses.


Use of Proceeds


Unless otherwise indicated in a prospectus supplement, the net proceeds from our sale of the securities will be used for general corporate purposes and other business opportunities.


We will not receive any of the proceeds from the sale of any common shares offered by the selling shareholder.